Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The transcription factor c-MYC is crucial in breast cancer development and is regulated by phosphorylation at serine 62 (S62).
• Protein Phosphatase 2A (PP2A) dephosphorylates c-MYC at S62, acting as a tumor suppressor by inhibiting c-MYC activity.
• Endogenous PP2A inhibitors, SET and CIP2A, are overexpressed in breast cancer, leading to PP2A inactivation and promoting tumorigenesis.

Purpose of the Study:

• To investigate the role of SET and CIP2A in breast cancer.
• To evaluate the therapeutic potential of inhibiting SET and CIP2A to target c-MYC.
• To explore a novel antitumor strategy by activating PP2A in breast cancer.

Main Methods:

• Assessed SET and CIP2A expression levels in breast cancer samples.
• Utilized knockdown techniques to reduce SET and CIP2A levels in breast cancer cell lines.
• Administered OP449, a SET antagonist, to breast cancer cells in vitro and in vivo.
• Measured c-MYC phosphorylation at S62, c-MYC activity, and target gene expression.

Main Results:

• SET and CIP2A were found to be overexpressed in a significant percentage of breast cancers (50-60% and ~90%, respectively).
• Knockdown of SET or CIP2A diminished the tumorigenic potential of breast cancer cells.
• Treatment with the SET antagonist OP449 reduced tumor growth, induced apoptosis, decreased c-MYC S62 phosphorylation, and lowered c-MYC activity.

Conclusions:

• SET and CIP2A are key drivers of breast cancer progression by inactivating the tumor suppressor PP2A.
• Inhibiting PP2A inhibitors like SET and CIP2A represents a promising strategy for breast cancer treatment.
• Activating PP2A through antagonism of its inhibitors offers a novel approach to target c-MYC posttranslationally in breast cancer therapy.